Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:25:32.767Z.
Calculation as of: 2026-10-06T13:25:32.767Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2f90c369cc2bba861e7882df5fb589e6a534c6c6a3ec3aca589af2a274c9b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Anteris Technologies Global Corp.
Market Cap
$734.10M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$709.33M
EV/EBIT Ratio
9.07x
TTM Avg
12.78x
3Y Avg
12.26x
5Y Avg
15.40x
Market Cap
$767.46M
EV/EBIT Ratio
N/A
TTM Avg
877.08x
3Y Avg
871.89x
5Y Avg
871.89x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $734.10M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 9.07x | 12.78x | 12.26x | 15.40x |
| Helus Pharma Inc. (HELP)vs › | $707.86M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | N/A | 877.08x | 871.89x | 871.89x |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $776.24M | N/A | 957.13x | 957.13x | 957.13x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
